Aug 14, 2026 05:02PM
Jun 3, 2026 08:02AM
Jun 3, 2026 08:00AM
Jun 3, 2026 07:25AM
Jun 1, 2026 08:01AM
Jun 1, 2026 08:00AM
Jun 1, 2026 07:01AM Actinium Pharmaceuticals presents CAR optimization data at SNMMI 2026
Jun 1, 2026 07:00AM
May 29, 2026 05:31PM
May 29, 2026 05:30PM
May 6, 2026 08:00AM
Apr 22, 2026 07:01AM
Apr 22, 2026 07:01AM
Apr 22, 2026 07:00AM Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer
Apr 22, 2026 07:00AM
Apr 6, 2026 07:30AM
Apr 6, 2026 07:30AM
Feb 17, 2026 07:42AM
Dec 12, 2025 08:45AM
Dec 12, 2025 08:45AM
Dec 1, 2025 08:45AM Actinium to present ATNM-400 breast cancer data at medical symposium
Dec 1, 2025 08:45AM
Nov 4, 2025 07:30AM
Nov 3, 2025 08:30AM
Oct 27, 2025 07:00AM
Oct 27, 2025 07:00AM
Oct 24, 2025 08:30AM
Oct 24, 2025 08:30AM Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation
Oct 13, 2025 12:10PM
Oct 13, 2025 08:30AM
Jul 31, 2025 08:31AM
Jul 31, 2025 08:30AM
Jun 23, 2025 11:31AM
Jun 23, 2025 11:30AM
May 26, 2025 10:20AM INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
May 25, 2025 09:03AM
May 24, 2025 08:50AM
May 22, 2025 04:00PM
May 22, 2025 09:00AM
May 21, 2025 09:53AM
May 19, 2025 06:40PM
May 18, 2025 10:00AM INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
May 17, 2025 08:03AM
May 16, 2025 04:00PM
May 15, 2025 10:20AM
May 13, 2025 09:00AM
May 12, 2025 05:48PM
May 11, 2025 04:00PM
May 10, 2025 08:04AM INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
May 9, 2025 08:00AM

329,911 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All